These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 18678377)

  • 21. Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.
    Chiba K; Adachi K
    Future Med Chem; 2012 Apr; 4(6):771-81. PubMed ID: 22530640
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.
    Mehling M; Brinkmann V; Antel J; Bar-Or A; Goebels N; Vedrine C; Kristofic C; Kuhle J; Lindberg RL; Kappos L
    Neurology; 2008 Oct; 71(16):1261-7. PubMed ID: 18852441
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
    Mehling M; Johnson TA; Antel J; Kappos L; Bar-Or A
    Neurology; 2011 Feb; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy.
    Groves A; Kihara Y; Chun J
    J Neurol Sci; 2013 May; 328(1-2):9-18. PubMed ID: 23518370
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.
    Choi JW; Gardell SE; Herr DR; Rivera R; Lee CW; Noguchi K; Teo ST; Yung YC; Lu M; Kennedy G; Chun J
    Proc Natl Acad Sci U S A; 2011 Jan; 108(2):751-6. PubMed ID: 21177428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage.
    Foster CA; Mechtcheriakova D; Storch MK; Balatoni B; Howard LM; Bornancin F; Wlachos A; Sobanov J; Kinnunen A; Baumruker T
    Brain Pathol; 2009 Apr; 19(2):254-66. PubMed ID: 18540945
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
    Brinkmann V
    Br J Pharmacol; 2009 Nov; 158(5):1173-82. PubMed ID: 19814729
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of FTY720 in the Theiler's virus model of multiple sclerosis.
    Li L; Matsumoto M; Seabrook TJ; Cojean C; Brinkman V; Pachner AR
    J Neurol Sci; 2011 Sep; 308(1-2):41-8. PubMed ID: 21726878
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FTY720 ameliorates experimental autoimmune neuritis by inhibition of lymphocyte and monocyte infiltration into peripheral nerves.
    Zhang Z; Zhang ZY; Fauser U; Schluesener HJ
    Exp Neurol; 2008 Apr; 210(2):681-90. PubMed ID: 18261728
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FTY720 ameliorates oxazolone colitis in mice by directly affecting T helper type 2 functions.
    Daniel C; Sartory NA; Zahn N; Schmidt R; Geisslinger G; Radeke HH; Stein JM
    Mol Immunol; 2007 Jul; 44(13):3305-16. PubMed ID: 17475330
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of sphingosine 1-phosphate modulation on immune outcomes.
    Pinschewer DD; Brinkmann V; Merkler D
    Neurology; 2011 Feb; 76(8 Suppl 3):S15-9. PubMed ID: 21339486
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ascomycete derivative to MS therapeutic: S1P receptor modulator FTY720.
    Hiestand PC; Rausch M; Meier DP; Foster CA
    Prog Drug Res; 2008; 66():361, 363-81. PubMed ID: 18416311
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Basic mechanisms of action of fingolimod in relation to multiple sclerosis].
    García-Merino JA; Sánchez AJ
    Rev Neurol; 2012 Jul; 55(1):31-7. PubMed ID: 22718407
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice.
    Nofer JR; Bot M; Brodde M; Taylor PJ; Salm P; Brinkmann V; van Berkel T; Assmann G; Biessen EA
    Circulation; 2007 Jan; 115(4):501-8. PubMed ID: 17242282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fingolimod: a novel immunosuppressant for multiple sclerosis.
    Brown BA; Kantesaria PP; McDevitt LM
    Ann Pharmacother; 2007 Oct; 41(10):1660-8. PubMed ID: 17785617
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of p38MAPK in S1P receptor-mediated differentiation of human oligodendrocyte progenitors.
    Cui QL; Fang J; Kennedy TE; Almazan G; Antel JP
    Glia; 2014 Aug; 62(8):1361-75. PubMed ID: 24810969
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fingolimod and sphingosine-1-phosphate--modifiers of lymphocyte migration.
    Massberg S; von Andrian UH
    N Engl J Med; 2006 Sep; 355(11):1088-91. PubMed ID: 16971715
    [No Abstract]   [Full Text] [Related]  

  • 38. Sphingosine-1-phosphate and FTY720 as anti-atherosclerotic lipid compounds.
    Tölle M; Levkau B; Kleuser B; van der Giet M
    Eur J Clin Invest; 2007 Mar; 37(3):171-9. PubMed ID: 17359484
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distinct properties of circulating CD8+ T cells in FTY720-treated patients with multiple sclerosis.
    Johnson TA; Lapierre Y; Bar-Or A; Antel JP
    Arch Neurol; 2010 Dec; 67(12):1449-55. PubMed ID: 21149809
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions.
    Van Doorn R; Van Horssen J; Verzijl D; Witte M; Ronken E; Van Het Hof B; Lakeman K; Dijkstra CD; Van Der Valk P; Reijerkerk A; Alewijnse AE; Peters SL; De Vries HE
    Glia; 2010 Sep; 58(12):1465-76. PubMed ID: 20648639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.